Vaccinex AI Stock Analysis
Want to see VCNX full AI Analyst Report?
Vaccinex (VCNX) AI Stock Analysis
Vaccinex
(Other OTC:VCNX)
The score is primarily constrained by weak financial performance—persistent losses, ongoing cash burn, and negative equity with higher debt—despite strong revenue acceleration and high gross margins. Technicals are mixed with a weak longer-term trend, and valuation is hindered by a negative P/E and no dividend support.
Vaccinex (VCNX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.01M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,806
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 2.05
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 25
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Vaccinex Business Overview & Revenue Model
Company Description
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate trea...
How the Company Makes Money
Vaccinex has historically not had meaningful recurring revenue from product sales because it has not broadly commercialized an approved therapeutic product. As a clinical-stage biotech, its funding and any revenue have typically been driven by (1) co...
Vaccinex Financial Statement Overview
Summary
Revenue growth is a positive (2025 revenue up ~249% to ~$2.10M) and gross margin is very strong, but the core financial picture remains high-risk: sizable net loss (~$5.26M), ongoing multi-year cash burn (2025 operating cash flow about -$6.45M), and a stressed balance sheet with negative equity (~-$7.59M) and higher debt (~$5.52M).
Income Statement
18Very NegativeBalance Sheet
12Very NegativeCash Flow
14Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 601.00K | 2.10M | 601.00K | 570.00K | 100.00K | 900.00K |
| Gross Profit | 574.00K | 2.06M | 601.00K | 570.00K | 68.00K | 731.00K |
| EBITDA | -18.51M | -5.20M | -18.54M | -19.75M | -19.61M | -21.40M |
| Net Income | -18.63M | -5.26M | -18.63M | -20.25M | -19.72M | -22.38M |
Balance Sheet | ||||||
| Total Assets | 2.60M | 1.80M | 2.60M | 3.63M | 7.98M | 9.84M |
| Cash, Cash Equivalents and Short-Term Investments | 1.11M | 140.00K | 1.11M | 1.53M | 6.39M | 8.59M |
| Total Debt | 25.00K | 5.52M | 25.00K | 247.00K | 485.00K | 390.00K |
| Total Liabilities | 5.08M | 9.39M | 5.08M | 5.94M | 2.78M | 2.43M |
| Stockholders Equity | -2.49M | -7.59M | -2.49M | -2.31M | 5.19M | 7.41M |
Cash Flow | ||||||
| Free Cash Flow | -16.21M | -6.46M | -16.21M | -17.30M | -19.17M | -25.33M |
| Operating Cash Flow | -16.19M | -6.45M | -16.19M | -17.23M | -19.07M | -25.30M |
| Investing Cash Flow | -22.00K | -9,000 | -22.00K | -67.00K | -99.00K | -32.00K |
| Financing Cash Flow | 15.78M | 5.49M | 15.78M | 12.45M | 16.98M | 23.32M |
Vaccinex Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VCNX, the sentiment is Positive. The current price of 1.00 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 0.96, and below the 200-day MA of 1.02, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 58.07 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VCNX.
Vaccinex Risk Analysis
Vaccinex disclosed 49 risk factors in its most recent earnings report. Vaccinex reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksVaccinex Peers Comparison
Overall Rating
- VCNX44Neutral
GTBP43Neutral
TOVX42Neutral
AZTR41Neutral
REVB41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| VCNX | 44Neutral | $2.68M | -0.38 | 104.38% | ― | ― | ― |
| GTBP | 43Neutral | $7.91M | -0.04 | -443.08% | ― | ― | 75.09% |
| TOVX | 42Neutral | $7.34M | -0.58 | -64.99% | ― | ― | 95.48% |
| AZTR | 41Neutral | $4.05M | -0.09 | -191.57% | ― | ― | 87.93% |
| REVB | 41Neutral | $2.99M | -0.11 | -124.23% | ― | ― | 94.95% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VCNX | Vaccinex | 1.00 | 0.34 | 51.52% | |
| TOVX | Theriva Biologics, Inc. | 0.14 | -0.09 | -39.24% | |
| GTBP | Gt Biopharma, Inc. | 3.72 | -13.46 | -78.35% | |
| REVB | Revelation Biosciences Inc. | 4.26 | -20.46 | -82.75% | |
| CERO | Cero Therapeutics Holdings, Inc. | 0.01 | -0.06 | -86.30% | |
| AZTR | Azitra Inc | 0.61 | -2.78 | -82.08% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026